LY307161 SR, a long-acting GLP-1 analog, improved glycemic control in patients with type 2 diabetes

被引：0
|
作者：
Trautmann, M
Chen, CF
Chappell, J
Dananberg, J
Patterson, B
Klausmann, G
Kapitza, C
机构：
来源：
DIABETES | 2003年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A136 / A136
页数：1
相关论文
共 50 条
  • [21] Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes
    Zheng, Xuemin
    Li, Ying
    Li, Xin
    Tang, Lida
    Xu, Weiren
    Gong, Min
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 93 (03) : 410 - 420
  • [22] Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes
    Setji, Tracy
    Feinglos, Mark
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (03) : 229 - 238
  • [23] The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs
    Rodbard, Helena W.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : 33 - 41
  • [24] Glycemic and Metabolic Effects of Long-Acting GLP-1 in T1D
    Mohandas, Deene
    Gao, Catherine
    Calma, Jamie
    Basina, Marina
    DIABETES, 2022, 71
  • [25] Monotherapy with the Once Weekly Long-Acting GLP-1 Analog LY2189265 for 12 Weeks in Patients with Type 2 Diabetes: Dose-Dependent Effects on Glycemic Control in a Randomized, Double-Blind, Placebo-Controlled Study
    Grunberger, George
    Chang, Anna
    Garcia Soria, Martin Gustavo
    Botros, Fady T.
    Bsharat, Rebhi
    Milicevic, Zvonko
    DIABETES, 2011, 60 : A300 - A300
  • [26] Human GLP-1α and GIPα:: novel, long-acting nanomedicines for type II diabetes mellitus
    Rubinstein, Israel
    Lim, Sok Bee
    Jeon, Eunjung
    Oenyueksel, Hayat
    FASEB JOURNAL, 2007, 21 (05): : A434 - A434
  • [27] Long acting GLP-1 for the treatment of type I diabetes
    Reichstetter, Sandra
    Castillo, Gerardo
    Medarova, Zdravka
    Moore, Anna
    Perfetti, Riccardo
    Leahy, Mark
    Bolotin, Elijah
    DIABETES, 2007, 56 : A73 - A73
  • [28] The long-acting GLP-1 derivative, NN2211, a new agent for the treatment of Type 2 diabetes
    Matthews, D
    Madsbad, S
    Schmitz, O
    Langendorf, KW
    Jakobsen, G
    DIABETES, 2002, 51 : A84 - A84
  • [29] Albiglutide, a long-acting GLP-1 mimetic: pharmacodynamics, pharmacokinetics, safety and tolerability in subjects with type 2 diabetes
    Stewart, M. W.
    Matthews, J.
    De Boever, E. H.
    Dobbins, R. L.
    Hodge, R. J.
    Walker, S. E.
    Holland, C. H.
    Bush, M. A.
    DIABETOLOGIA, 2008, 51 : S347 - S347
  • [30] The Gastrointestinal Adverse Event Profile of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
    Stewart, Murray W.
    Reusch, Jane E. B.
    Bush, Mark A.
    Yang, Fred
    Rosenstock, Julio
    DIABETES, 2009, 58 : A161 - A161
12345